Ryan Specialty Q2 Organic Growth Slips to 6.7%, Breaking Bull Thesis

What happened

Ryan Specialty’s second-quarter 2026 revenue rose 7.2% to $917 million, but organic growth came in at just 6.7%, well short of the 9%–11% baseline needed to sustain the investment case. The slowdown reflects intensifying property insurance pricing pressure and rising competition, which management had flagged as headwinds. Total revenue benefited from modest acquisition contributions, masking the weakening organic core. This print follows prior quarters of volatility and suggests the company cannot outgrow a softening cycle through hiring alone. With margins already under strain from talent spending, the growth miss cements the bear scenario and invalidates the thesis of resilient high-single-digit expansion.

Implication

The 6.7% organic growth confirms the bear case, which implies a fair value near $32—well below recent levels. Property reinsurance rates are still declining, creating further commission headwinds. High leverage (4.88x net debt/EBITDA) leaves no buffer if cash flows weaken. Management may be forced to cut guidance again, spurring multiple compression. Until organic growth stabilizes and margins find a floor, the risk-reward remains sharply negative for shareholders.

Thesis delta

The prior thesis awaited evidence of sustained 9%+ organic growth; Q2 2026’s 6.7% print, coupled with ongoing property softness, breaks that expectation. The growth narrative has shifted from ‘prove it’ to ‘broken,’ demanding an immediate downgrade to the bear case valuation of around $32. Without a quick reversal in pricing or market share, the stock faces material downside.